Drug Profile
PPL 100
Alternative Names: MK-8122; PL-100; PPL-100; TMB-607Latest Information Update: 22 May 2020
Price :
$50
*
At a glance
- Originator Ambrilia Biopharma
- Developer Ambrilia Biopharma; TaiMed Biologics; Temple University
- Class Aniline compounds; Antiretrovirals; Benzhydryl compounds; Carbamates; Phosphoric acid esters; Small molecules; Sulfonamides
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 08 May 2020 TaiMed Biologics terminates a phase I trial for HIV infections (In volunteers) in USA (NCT03110549)
- 28 Dec 2019 No recent reports of development identified for phase-I development in HIV-infections(In volunteers) in USA (IM, Injection)
- 28 Dec 2019 No recent reports of development identified for phase-I development in HIV-infections(In volunteers) in USA (SC, Injection)